Last reviewed · How we verify

DTaP-IPV-Hep B-PRP-T Vaccine

Sanofi Pasteur, a Sanofi Company · Phase 3 active Biologic

DTaP-IPV-Hep B-PRP-T Vaccine is a vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children.

This pentavalent vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b.

This pentavalent vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b. Used for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children.

At a glance

Generic nameDTaP-IPV-Hep B-PRP-T Vaccine
SponsorSanofi Pasteur, a Sanofi Company
Drug classvaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

DTaP-IPV-Hep B-PRP-T is a combination vaccine containing inactivated toxoids (diphtheria and tetanus), acellular pertussis antigens, inactivated poliovirus, hepatitis B surface antigen, and polyribosylribitol phosphate conjugate from Haemophilus influenzae type b. Upon administration, these antigens trigger both humoral (antibody) and cell-mediated immune responses, providing protection against six serious infectious diseases. The conjugate technology for the Hib component enhances immunogenicity in infants by linking the polysaccharide capsule to a protein carrier.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTaP-IPV-Hep B-PRP-T Vaccine

What is DTaP-IPV-Hep B-PRP-T Vaccine?

DTaP-IPV-Hep B-PRP-T Vaccine is a vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children.

How does DTaP-IPV-Hep B-PRP-T Vaccine work?

This pentavalent vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b.

What is DTaP-IPV-Hep B-PRP-T Vaccine used for?

DTaP-IPV-Hep B-PRP-T Vaccine is indicated for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children.

Who makes DTaP-IPV-Hep B-PRP-T Vaccine?

DTaP-IPV-Hep B-PRP-T Vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

What drug class is DTaP-IPV-Hep B-PRP-T Vaccine in?

DTaP-IPV-Hep B-PRP-T Vaccine belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is DTaP-IPV-Hep B-PRP-T Vaccine in?

DTaP-IPV-Hep B-PRP-T Vaccine is in Phase 3.

What are the side effects of DTaP-IPV-Hep B-PRP-T Vaccine?

Common side effects of DTaP-IPV-Hep B-PRP-T Vaccine include Injection site reactions (pain, redness, swelling), Fever, Irritability, Drowsiness, Loss of appetite.

Related